Fenping Zheng

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 6

Top Topics

Nlrp Inflammasome

Top Venues

Hepatology communications

Journal of molecular endocrinology

This page only lists publications with an associated author ORCID identifier.

Publications

Shaohan Huang, Beibei Wu, Yingzi He, Ruojun Qiu, Tian Yang, Shuo Wang, Yongzhen Lei, Hong Li, Fenping Zheng
Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway. Hepatology communications 7 (3) (2023)
Shaohan Huang, Beibei Wu, Yingzi He, Ruojun Qiu, Tian Yang, Shuo Wang, Yongzhen Lei, Hong Li, Fenping Zheng
Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway. Hepatology communications 7 (3) (2023)
Shaohan Huang, Beibei Wu, Yingzi He, Ruojun Qiu, Tian Yang, Shuo Wang, Yongzhen Lei, Hong Li, Fenping Zheng
Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway. Hepatology communications 7 (3) (2023)
Beibei Wu, Ruojun Qiu, Shuo Wang, Yingzi He, Jing Wang, Zhiye Xu, Xihua Lin, Hong Li, Fenping Zheng
Transthyretin knockdown recapitulates the insulin-sensitizing effects of exercise and promotes skeletal muscle adaptation to exercise endurance. Journal of molecular endocrinology 71 (1) (2023)
Shaohan Huang, Beibei Wu, Yingzi He, Ruojun Qiu, Tian Yang, Shuo Wang, Yongzhen Lei, Hong Li, Fenping Zheng
Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway. Hepatology communications 7 (3) (2023)
Shaohan Huang, Beibei Wu, Yingzi He, Ruojun Qiu, Tian Yang, Shuo Wang, Yongzhen Lei, Hong Li, Fenping Zheng
Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway. Hepatology communications 7 (3) (2023)